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ABSTRACT
Thyroid nodules are frequent findings, especially when sensitive imaging methods are used. Al-
though thyroid cancer is relatively rare, its incidence is increasing, particularly in terms of small 
tumors, which have an uncertain clinical relevance. Most patients with differentiated thyroid 
cancer exhibit satisfactory clinical outcomes when treatment is appropriate, and their morta-
lity rate is similar to that of the overall population. However, relapse occurs in a considerable 
fraction of these patients, and some patients stop responding to conventional treatment and 
eventually die from their disease. Therefore, the challenge is how to identify the individuals 
who require more aggressive disease management while sparing the majority of patients from 
unnecessary treatments and procedures. We have updated the Brazilian Consensus that was 
published in 2007, emphasizing the diagnostic and therapeutic advances that the participants, 
representing several Brazilian university centers, consider most relevant in clinical practice. The 
formulation of the present guidelines was based on the participants’ experience and a review 
of the relevant literature. Arq Bras Endocrinol Metab. 2013;57(4):240-64
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RESUMO
Nódulos tireoidianos são muito frequentes, sobretudo quando se empregam métodos sensí-
veis de imagem. Embora o câncer seja proporcionalmente raro, sua incidência vem aumen-
tando, especialmente de tumores pequenos, cuja evolução clínica é incerta. A maioria dos pa-
cientes com carcinoma diferenciado de tireoide evolui bem quando adequadamente tratada, 
com índices de mortalidade similares à população geral. Por outro lado, um percentual não 
desprezível apresenta recidivas e alguns eventualmente não respondem às terapias convencio-
nais, evoluindo para óbito. Assim, o desafio é distinguir os pacientes merecedores de condutas 
mais agressivas e, ao mesmo tempo e não menos importante, poupar a maioria de tratamen-
tos e procedimentos desnecessários. Atualizamos o Consenso Brasileiro publicado em 2007, 
ressaltando os avanços diagnósticos e terapêuticos que os participantes, de diferentes Centros 
Universitários do Brasil, consideram mais relevantes para prática clínica. A elaboração dessas 
diretrizes foi baseada na experiência dos participantes e revisão da literatura pertinente. Arq Bras 
Endocrinol Metab. 2013;57(4):240-64
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INTRODUCTION
S everal thyroid diseases may present as nodules. According to population-based studies conduc-
ted with adults in iodine sufficient areas, approxima-
tely 4 to 7% of women and 1% of men exhibit palpa-
ble thyroid nodules (1,2). However, the prevalence of 
nodules indicated by ultrasound exams (US) is subs-
tantially higher, reaching up to 68% of the population 
(3,4); such high frequencies are usually found among 
older women (5). Although most thyroid nodules are 
benign, the possibility of a malignancy must be ruled 
out; 95% of malignant tumors are well-differentiated 
carcinomas (6,7).
Although the current incidence of thyroid cancer 
is not higher than 24 cases per 100,000 people (7), 
the incidence has been increasing in recent years (7) 
to become the fourth most common type of malignant 
tumor among Brazilian women (8). This increased in-
cidence is mostly associated with a greater number of 
small papillary carcinomas (6).
The recommendations described here were pre-
pared according to the model provided by Pro-
ject Guidelines (Projeto Diretrizes) by the Brazilian 
Medical Association (Associação Médica Brasileira – 
AMB) and Federal Council of Medicine (Conselho 
Federal de Medicina – CFM) (9), which is a nation-
wide initiative already known to the Brazilian medical 
and academic communities. Consistently, the recom-
mendation levels or the strength of evidence degrees 
employed by that model were used, as described in 
Table 1 (9).
Following the selection of participants with estab-
lished academic activity and clinical experience relat-
ed to the thyroid, the clinical questions that ground-
ed the recommendations were elaborated upon. The 
corresponding literature was located in the Med-
Line-PubMed, EMBASE, and SciELO-LILACS da-
tabases.
APPROACH TO PATIENTS WITH THYROID 
NODULES
What clinical information must be collected?
With regard to patients with thyroid nodules, a tho-
rough clinical interview and physical examination must 
be performed. Although these methods are most often 
neither sensitive nor specific, some of the data they pro-
vide are indicative of a higher risk of malignancy (5,10-
14) (Table 2).
Table 1. Recommendations according to the level of evidence (9)
Recommendation Strength of evidence
A
Experimental and observational studies with better 
consistency 
B
Experimental and observational studies with less 
consistency
C Case reports (non-controlled studies)
D
Opinion lacking critical assessment, based on 
consensus, physiological studies, or animal models 
Table 2. Data from the clinical history and physical examination that 
suggest a greater risk of malignancy in thyroid nodules
Male gender; age < 20 or > 70 years old; history of exposure to ionizing 
radiation or neck radiotherapy in childhood or adolescence; previous diagnosis 
of thyroid cancer treated by means of partial thyroidectomy
Family (first degree) history of thyroid cancer, especially when affecting two or 
more relatives in the case of differentiated carcinoma
Hereditary syndromes such as multiple endocrine neoplasia type 2 (MEN II), 
Cowden syndrome, Pendred syndrome, Werner syndrome, Carney complex, 
and familial adenomatous polyposis
Fast-growing or large nodules with compressive symptomsa
Hard nodules, adhered to deep tissues, with little mobility; associated with 
paralysis of the ipsilateral vocal cord; or cervical lymphadenopathya
Nodules incidentally detected on FDG-PET (focal uptake) in cancer patients 
a Confirmation of these data as being suspicious of malignancy requires comparison with the 
results of imaging exams.
As will be subsequently shown, nodules that are 
large or are considered suspicious upon a US exam 
must be subjected to fine needle aspiration (FNA) 
biop sy, regardless of the patient’s clinical history. Con-
versely, nodules that are small and are not considered 
suspicious upon US require further investigation only 
in patients with high clinical risk of malignancy, in 
which case the personal and family history become sig-
nificantly relevant.
Recommendation 1
Individuals with a personal or family history of thyroid 
cancer, a history of exposure to radiation in childhood 
or adolescence, or nodules incidentally discovered on 
fluorodeoxyglucose positron emission tomography 
(FDG-PET; focal uptake) are considered to be at high 
risk for thyroid malignancy (Recommendation B).
What are the recommended laboratory tests?
Serum thyroid-stimulating hormone (TSH)
As clinical assessment is not always indicative of thyroid 
dysfunction, TSH levels must be measured.
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Whenever hyperfunction is detected, even when it is 
subclinical, thyroid scintigraphy, preferably with radio-
active iodine (RAI), is indicated to establish whether 
the nodule has high or low uptake. In approximately 
10% of the patients with solitary nodules, TSH is sup-
pressed and the nodule has high uptake. In such cases, 
FNA is unnecessary because this type of nodule is ex-
ceptionally malignant (5,15).
When TSH levels are elevated, the levels of anti-
thyroid peroxidase (anti-TPO) antibodies may be mea-
sured to confirm a diagnosis of autoimmune thyroiditis. 
When the US shows a well-defined nodule, the criteria 
to indicate an FNA are the same in patients with and 
without Hashimoto’s thyroiditis (16). Although some 
studies have shown a direct correlation between serum 
TSH levels and risk of malignancy in thyroid nodules 
and even with initial staging (17,18), the currently 
available data do not support the indication of any par-
ticular approach of patients with thyroid nodules and 
normal-to-high or high TSH levels.
Serum calcitonin and thyroglobulin levels 
Several studies have assessed the utility of serum (basal 
and stimulated) calcitonin for early diagnosis of spo-
radic medullary thyroid carcinoma (MTC) in patients 
with thyroid nodules (19-22). However, the interpreta-
tion of calcitonin (basal and stimulated) results and the 
cost-benefit ratio are controversial and may be more 
interesting in patients who have small nodules and are 
over 40 years of age (21). The sensitivity and specificity 
of the serum thyroglobulin (Tg) levels are relatively low 
for the diagnosis of thyroid cancer (23).
Recommendation 2
Serum TSH levels must be measured at the initial assess-
ment, primarily to eliminate the possibility of autonomous 
or hyperfunctioning nodules (Recommendation A).
Recommendation 3
Except for patients with clinical suspicion or family his-
tory of MTC or multiple endocrine neoplasia type 2 
(MEN II), measurement of serum calcitonin is not ne-
cessary (Recommendation C).
Recommendation 4
Serum Tg levels are not recommended to distinguish 
between benign and malignant thyroid nodules (Re-
commendation B).
What is the role of the imaging methods?
Neck ultrasound
US is an excellent method for the detection of thyroid 
nodules, with a sensitivity of approximately 95% (24), 
which is higher than other sophisticated methods such 
as computed tomography (CT) and magnetic resonan-
ce imaging (MRI) and often results in modifications of 
decisions exclusively based on the findings upon palpa-
tion (25). US allows for the assessment of the nodule 
size, composition, and characteristics. In addition, US 
might detect suspicious lymph nodes in the neck and 
eventually the compression or invasion of thyroid adja-
cent structures (26).
US is also used in diagnostic (e.g., directed FNA) 
and therapeutic (e.g., cyst aspiration, ethanol injec-
tion, laser therapy) procedures and to monitor nodule 
growth.
Some US findings are associated with increased risk 
of malignancy. Such findings include hypoechogenicity 
(especially if there is marked hypoechogenicity); micro-
calcifications; irregular margins; predominantly or ex-
clusively central vascularization detected by Doppler; 
larger anteroposterior diameter compared with the 
transverse diameter (27-31); and, more specifically, the 
detection of lymph nodes of the neck with suspicious 
characteristics. Nevertheless, US findings alone do not 
allow for absolute differentiation between benign and 
malignant lesions (24).
Assessment of the nodule elasticity (elastography) 
demonstrates greater rigidity in malignant tumors. Al-
though elastography cannot replace conventional US, 
when performed together (elastography plus US), the 
sensitivity and specificity of the assessment improve 
(32). In addition, the instances in which elastography 
might be clinically decisive when combined with US 
must still be established as well as its limitations and 
potential means of minimizing these limitations (33).
Recommendation 5
Neck US must be performed in all patients with thyroid 
nodules (Recommendation A).
Computed tomography, magnetic resonance imaging, 
and positron emission tomography
Neither CT nor MRI can differentiate between benign 
and malignant lesions as well as US; therefore, these 
methods are seldom indicated for the assessment of 
thyroid nodules. However, these imaging modalities 
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are useful in the assessment of substernal goiter and the 
compression or invasion of adjacent structures, such as 
the trachea (34). Although 18FDG-PET is useful in the 
differentiation between benign and malignant lesions 
(35), this technique is still not readily accessible and is 
quite expensive. In addition, this sophisticated techni-
que does not allow for the dismissal of FNA and might 
be more useful for the cases with undetermined cyto-
logy (35).
Recommendation 6
CT, MRI, and FDG-PET are seldom necessary for the 
assessment of thyroid nodules (Recommendation B). 
Isotope scintigraphy
Scintigraphy with radionuclides is important to deter-
mine whether nodules are hyperfunctioning. Hyper-
functioning nodules with or without extra-nodular 
suppression are exceptionally malignant (5,15). Scin-
tigraphy may be performed with 131I or 123I or 99mTc 
pertechnetate. The iodine radioisotopes are absorbed 
and organified by the thyroid and are the preferred iso-
types because 3 to 8% of nodules that are hyperfunctio-
ning when mapped with 99mTc scans are hypofunctio-
ning with iodine (36). Scintigraphy is also indicated for 
nodules with cytology, which is suggestive of follicular 
tumor in patients with normal low or low TSH, if it was 
not performed earlier (37).
Recommendation 7
Thyroid scintigraphy is indicated when a functioning 
nodule is suspected (subnormal TSH) (Recommen-
dation A) or cytology is suggestive of follicular tumor 
(Recommendation B).
When is a fine needle aspiration biopsy indicated?
FNA is the best available method to distinguish be-
tween benign and malignant lesions (5), even in the 
case of nodules smaller than 1 cm (3) or larger than 
4 cm (38). In addition, FNA is an easy and low-cost 
outpatient procedure that is virtually devoid of serious 
complications. Nevertheless, we emphasize the im-
portance of having an experienced physician perform 
this procedure as well as the necessity of an experien-
ced cytopathologist who can accurately analyze the 
biopsy material. 
Thyroid nodules smaller than 1 cm represent micro-
carcinomas in a considerable percentage of cases (3). 
Nevertheless, the high frequency of microcarcinomas 
found only in autopsies (39), their low rate of progres-
sion even when untreated (40,41), and the fact that the 
probability of a cure is not affected when treatment is 
delayed until the tumor exhibits growth (40) minimize 
the concerns associated with the detection of microcar-
cinomas. Consistently, the investigation focuses on the 
diagnosis of carcinomas larger than 1 cm. 
Recommendation 8
When hyperfunctioning or purely cystic nodules have 
been ruled out, the indication for FNA is based on the 
patient’s clinical history, nodule size, and US findings 
(Recommendation B). These indications are summari-
zed in table 3.
Table 3. Indications for FNA in patients with thyroid nodules (except for 
hyperfunctioning or purely cystic nodules)
Nodule size FNA indicated
< 5 mm Not indicated
≥ 5 mm Patients with high risk of malignancy 
or suspicious nodule on USa
≥ 10 mm Solid hypoechoic noduleb
≥ 15 mm Solid iso- or hyperechoic noduleb
≥ 20 mm Complex or spongiform noduleb
Nodule with apparent extrathyroidal 
invasion
All
Suspicious lymph node upon US Lymph node FNA
a In nodules < 10 mm without apparent invasion or suspicious lymph nodes, monitoring with 
US, with FNA when the nodule exceeds 10 mm is considered acceptable. 
b Even without suspicious US findings.
What approaches follow from cytology?
The National Cancer Institute (NCI, USA) held a mul-
tidisciplinary conference, which established that the 
cytopathology results must reflect the cytopathologist’s 
diagnostic impression in a succinct and clear manner 
without leaving room for interpretative misunderstan-
dings. The classification system suggested for that pur-
pose, known as Bethesda System (42), is described in 
table 4. The approach of patients based on the cytology 
results is depicted below (Figure 1).
Recommendation 9
Surgery is recommended when cytology results indi-
cate a suspicious malignancy (Bethesda category V) 
or confirmed malignancy (Bethesda category VI) (Re-
commendation A).
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Figure 1. Suggested approach in patients with thyroid nodules. 
Thyroid nodule (except for pregnart women)
Normal or high TSH
FNA
131| or 123| scintigraphy
131| or 123| scintigraphyFNA not indicated
Suspicious for malignancy
or malignant
Follicular
neoplasm b
AUS/FLUS b
Unsatisfactory
Benign
Surgery a
Hypofunctioning
nodule: FNA
Hyperfunctioning
nodule
Hyperfunctioning
nodule
Hypofunctioning
nodule: surgery a 
Low TSH
Sugery a
Same result
Repeat FNA 3-6 
months later
Treatment or
monitoring with US c 
Monitoring with 
US c 
AUS, atypia of uncertain signicance; FLUS, follicular lesion of uncertain signicance.
a See the extent of surgery in R14, R15, R28, R30-32.
b When available, molecular markers are useful.
c See R24-26.
Nodule ≤ 2 cm,
low clinical and 
US suspicion
Nodule > 2 cm or
 high clinical or
US suspicion
Table 4. Bethesda system of thyroid cytopathology reports 
Category
I Non-diagnostic or unsatisfactory sample
II Benign
III Atypia/follicular lesion of undetermined significance
IV Follicular tumor or suspicious for follicular tumor
V Suspicious malignancy
VI Malignant
Recommendation 10
When the cytology results are indicative of a follicular 
tumor (Bethesda category IV), scintigraphy is useful for 
decision making. Removal of hyperfunctioning nodules 
is not mandatory; however, hypofunctioning nodules 
remain an indication for surgery (Recommendation B). 
Recommendation 11
When cytology indicates follicular lesion or atypia with 
undetermined significance (Bethesda category III), it is 
recommended to repeat the FNA 3 to 6 months later. 
When the results persist, surgery is indicated for pa-
tients with high clinical or ultrasonographic suspicion 
of malignancy or nodules larger than 2 cm. Patients 
with nodules ≤ 2 cm and low clinical and ultrasonogra-
phic suspicion of cancer should be monitored (Recom-
mendation C).
Recommendation 12
When the biopsy sample is unsatisfactory for cytologi-
cal analysis (Bethesda category I), it is recommended to 
repeat the US-directed FNA 3 to 6 months later (Re-
commendation B). When the results persist, surgery is 
indicated for patients with high clinical or ultrasono-
graphic suspicion of malignancy or nodules larger than 
2 cm. Patients with nodules ≤ 2 cm and low clinical and 
ultrasonographic suspicion of cancer should be moni-
tored (Recommendation C).
Some studies (43-45) have shown that when cyto-
logy is benign but the nodule exhibit a combination 
of US findings compatible with malignancy, repetition 
of the FNA can be useful, regardless of the nodule 
growth, as the rate of malignancy in such discordant 
cases is substantially higher than the traditional false-
negative rate of FNA, which varies from 1 to 3% (42).
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18FDG-PET helps rule out malignancy in thyroid 
nodules with undetermined cytology (35); however, as it 
is expensive and not readily accessible, 18FDG-PET is not 
recommended as a routine procedure in this context.
What is the utility of molecular markers?
Several molecular markers have been assessed, espe-
cially with regard to thyroid nodules with undetermi-
ned cytology. Markers such as HBME, galectin, and 
CK19, among others, can be measured by any labo-
ratory that performs routine immunohistochemical 
tests. Such markers are helpful in the identification 
of malignant tumors, particularly papillary carcinomas 
(46). Although their sensitivity reaches 0.85 to 0.93, 
their specificity varies from 0.43 to 0.71 at most (47). 
Mutations in specific genes (such as BRAF V600E and 
RAS) or gene rearrangements (such as RET/PTC and 
PAX8-PPARy) can also contribute to the identifica-
tion of malignancy (48). Unfortunately, a panel with 
these four markers (BRAF, RAS, and rearrangements 
RET/PTC and PAX8/PPARy) fails to identify 36% of 
malignant cases (sensitivity of 64%) in clinical practice 
(49). Other markers, such as microRNAs, are being 
investigated (50). Recently, a novel test designed to 
rule out malignancy exhibited a high negative predic-
tive value (95%) in nodules with undetermined cyto-
logy (51).
Recommendation 13
Molecular markers are helpful in defining the nature 
of thyroid nodules, especially those with undetermined 
cytology (Bethesda category III or IV) (Recommen-
dation A). Consistently, the surgical recommendations 
above (especially R10 and R11) may be modified when 
molecular markers are used.
What should the extent of the surgery be when 
malignancy is undetermined?
Recommendation 14
A total thyroidectomy is recommended under the follo-
wing conditions: (i) when a nodular disease is bilateral; 
(ii) when a nodular disease is associated with radiation; 
(iii) when the cytology is indicative of a suspicious ma-
lignancy; and (iv) when the cytology is undetermined 
and the nodule is > 4 cm or ≤ 4 cm but is associated 
with high clinical or US suspicion of cancer (Recom-
mendation B).
Recommendation 15
Lobectomy is considered sufficient in unilateral and 
sporadic nodular disease when (i) the nodule ≤ 4 cm, 
cytology is undetermined, and the clinical and ultraso-
nographic suspicion of malignancy is low or (ii) cytolo-
gy is unsatisfactory (Recommendation B).
As the pre-test malignancy risk is modified when 
molecular markers or FDG-PET scans are used, the ex-
tent of surgery described above may be modified based 
on their results.
What is the approach in children and adolescents?
Recommendation 16 
The recommendations described above also apply in 
the case of thyroid nodules in childhood and adoles-
cence (Recommendation B).
In pregnant women, scintigraphy with isotopes is 
contraindicated. Surgery increases the risk of miscarriage 
in the first trimester and of premature birth in the third 
trimester; therefore, surgery is safest when performed in 
the second trimester (52). In addition, delay of the onset 
of treatment of differentiated carcinoma diagnosed in 
pregnancy does not appear to be associated with disease 
progression or interference with the probability of a cure 
(53). Based on those premises, the recommendations in 
nodules detected during pregnancy are as follows:
Recommendation 17
Pregnant women with large nodules, apparent invasion, 
or suspicious lymph nodes on US must be subjected to 
FNA (Recommendation A). In the remainder of cases, 
when TSH levels are spontaneously suppressed, follow 
up with US is recommended (Recommendation B). 
When TSH levels are normal or high, FNA is indicated 
as described in table 3; however, monitoring with US 
(without FNA) is also acceptable (Recommendation B). 
Recommendation 18
When FNA is not performed in the initial assessment, 
it must be performed when the nodule exhibits signi-
ficant growth in the course of pregnancy (Recommen-
dation B). 
Recommendation 19
In case of undetermined cytology, surgery may be indi-
cated in the second trimester if there is significant no-
dule growth (Recommendation B). Surgery can also be 
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performed in the second trimester when the cytology 
indicates a suspicious malignancy or malignancy and 
the tumor exhibits significant growth or the disease is 
in an advanced stage (Recommendation B). TSH levels 
must be kept low (< 0.5 mIU/L) in patients with ma-
lignant cytology until surgery (Recommendation C). 
Recommendation 20
Following delivery, patient management should be re-
assessed according to the usual recommendations (Re-
commendation A).
When indicated, what are the non-surgical 
therapeutic options for benign nodular disease?
Several studies have suggested that the use of levo-
thyroxine (T4) with consequent reduction of TSH le-
vels suppresses nodule growth (54-56). However, the 
adverse effects of hormone therapy on the cardiovascu-
lar system and bone metabolism (57,58) limit its use.
Focal destruction by means of sclerotherapy with 
ethanol or laser photocoagulation can be considered 
in patients with benign solitary nodules (59,60). When 
the main problem is thyroid hyperfunction caused by an 
autonomous nodule, long-term anti-thyroid drug treat-
ment is an interesting option in elderly patients (60).
In several patients with multinodular goiter, iodine 
uptake is not homogeneous and is relatively low due to 
the presence of inactive nodules (i.e., “hypofunctioning” 
on scintigraphy) or suppression of the paranodular tissue. 
As such areas concentrate 131I very weakly, the efficacy of 
this treatment is compromised. The use of low doses of 
recombinant TSH significantly increases 131I uptake in 
such patients and allows even low activities to efficiently 
reduce the goiter size by 30 to 50% in one year (60-62).
Recommendation 21
Suppressive treatment with T4 is not recommended for 
thyroid benign nodular disease (Recommendation B).
Recommendation 22
Sclerotherapy with alcohol can be considered for cystic 
or predominantly cystic nodules (Recommendation B).
Recommendation 23
Treatment of a nontoxic multinodular goiter with 131I 
can be optimized through previous administration of 
low doses of recombinant TSH (Recommendation B).
How should the patients not subjected to surgery be 
monitored?
Although the malignancy risk of nodules without indi-
cation for FNA (63) or surgery is low [benign cytolo-
gy (5,42), small nodules with unsatisfactory cytology 
(64,65) or undetermined follicular lesions/atypia, and 
non-suspicious clinical history and US], monitoring 
with US is recommended to detect eventual nodule 
growth, although its low specificity for a malignancy 
diagnosis is an acknowledged fact (44,66). The interval 
between the US tests varies from 6 to 24 months and 
is defined depending on the number of previous asses-
sments and changes in the nodule size in relation to 
previous US(s).
Recommendation 24
When an FNA is not performed in the initial assess-
ment, it must be performed when the nodules meet the 
criteria listed in Table 3 (Recommendation B).
Recommendation 25
In cases of benign cytology, FNA must be repeated 
when the nodules exhibit significant growth (> 50% 
compared with the initial volume; Recommendation 
C).
Recommendation 26
Surgery must be considered for nodules that progress 
over time and whose initial cytology was undetermined 
or unsatisfactory (Recommendation B).
MANAGEMENT OF DIFFERENTIATED THYROID 
CARCINOMA 
In Brazil and worldwide, sensitive imaging methods 
such as US are becoming increasingly accessible to an 
aging population, thus increasing the number of indi-
viduals diagnosed with small nodules that, even when 
confirmed as malignant, exhibit uncertain progression. 
The high frequency of carcinomas that are only found 
during autopsies (39) and prospective studies conduc-
ted with Japanese patients with microcarcinomas not 
subjected to surgery (40,41) suggest that a large num-
ber of these tumors never exhibit clinical progression, 
which appears to account for the low mortality rate of 
differentiated thyroid carcinomas (DTCs) in spite of its 
increased incidence (6,7).
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Most patients with DTC exhibit good outcomes 
when they are appropriately treated. However, relapse 
occurs in a significant percentage of cases, and some 
of these cases stop responding to conventional treat-
ment and eventually die from their disease. The chal-
lenge, therefore, is to identify the individuals who re-
quire more aggressive management, while at the same 
time, and equally importantly, sparing the majority of 
patients from unnecessary treatments and procedures. 
Therefore, for the purpose of therapeutic planning and 
the definition of the best follow-up approach for pa-
tients with DTC, assessment of the risk of disease recur-
rence and progression is crucial. 
When must initial surgery be performed?
Thyroidectomy is indicated together with a DTC diag-
nosis. Nevertheless, patients with a low life expectancy 
due to an associated severe disease might be spared 
thyroidectomy and given palliative treatment in case 
of advanced or progressive disease. Similarly, when 
surgery represents a risk due to patient condition, but 
the patient is expected to improve, thyroidectomy 
might be delayed for some months, provided the tu-
mor is not progressing or growing (67). The same 
applies to women diagnosed at the beginning of preg-
nancy, who should also be subjected to monitoring 
with US. Surgery may be indicated in the second tri-
mester if the tumor is growing (see Recommendation 
19) or after labor if the tumor is stable (53). In the 
absence of contraindications, TSH levels must be su-
ppressed (< 0.5 mIU/L) in patients who will not un-
dergo surgery or must wait some months before the 
surgery is performed. 
Except for exceptional circumstances, any delay be-
tween DTC diagnosis and thyroidectomy is unjustified. 
What preoperative assessment is recommended?
Preoperative US must be performed to identify the tu-
mor multicentrality, which is supportive of the choice 
of total thyroidectomy as initial treatment, as well as to 
look for non-palpable lymph node metastases (26,68) 
because their presence requires modified neck dissec-
tion. Although it is not indicated for this purpose, US 
results may also suggest tracheal and/or esophageal in-
vasion by the tumor (26). Any suspicious lymph nodes 
must be assessed by FNA.
CT, MRI, esophagoscopy, or laryngotracheoscopy 
are not routinely recommended and are only indicated 
in case of clinical or ultrasonographic suspicion of inva-
sion of adjacent structures (69,70). The use of iodin-
ated contrast should be avoided; however, when iodin-
ated contrast is necessary to better assess the extent of 
disease, the therapy with 131I, when indicated, must be 
deferred for at least one month (71).
As permanent recurrent laryngeal nerve injury is 
uncommon when a thyroidectomy is performed by ex-
perienced surgeons, and seldom occurs asymptomati-
cally before surgery, we do not recommend a routine 
performance of preoperative video-laparoscopy. The 
same applies to the measurement of the serum calcium 
levels with regard to hypoparathyroidism. 
Recommendation 27
Preoperative neck US is recommended, even in asymp-
tomatic patients without palpable lymph nodes, to as-
sess the tumor multicentrality, the presence of lymph 
node metastases, and the extrathyroidal invasion (Re-
commendation B). No other study is routinely recom-
mended (Recommendation B).
What must the extent of the thyroidectomy be?
Total thyroidectomy is the most recommended sur-
gical procedure in patients with DTC. Lobectomy 
may be indicated in patients with classic, unifocal, 
sporadic papillary carcinoma ≤ 1 cm and without 
apparent lymphadenopathy or extrathyroidal inva-
sion (67,72-75).
In patients initially subjected to partial thyroidecto-
my, surgical complementation may be avoided in cases 
of papillary carcinoma presenting with the characteris-
tics described above as well as in cases of minimally in-
vasive follicular carcinoma and the capsulated follicular 
variant of papillary carcinoma (without vascular inva-
sion) measuring up to 2 cm.
Recommendation 28
Total thyroidectomy is the surgical procedure of choi-
ce in patients with a preoperative diagnosis of papillary 
carcinoma (Recommendation A).
Recommendation 29
The indication for surgical complementation in patients 
initially subjected to partial thyroidectomy must take 
into account the anatomical-pathological data in parti-
cular and the individual risk posed by the novel inter-
vention (Recommendation A).
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What is the surgical management of lymph nodes?
Lymph node metastases are frequent findings by the 
time the diagnosis of papillary cancer is established 
(76). As neck palpation does not produce abnormal fin-
dings in most cases (77), a preoperative US and careful 
perioperative assessment by the surgeon are needed. 
Whenever metastases are suspected based on US or du-
ring surgery, the patient should be subjected to a total 
thyroidectomy and therapeutic lymph node dissection, 
even in the case of tumors ≤ 1 cm, because full tumor 
resection improves prognosis (78).
Even when preoperative US and perioperative as-
sessment are negative, many patients with papillary 
carcinoma exhibit lymph node micrometastases in the 
central compartment (79). Nevertheless, there are no 
consistent data showing that elective dissection of those 
lymph nodes reduces the risk of relapse. Adjuvant the-
rapy with 131I and TSH suppression may help control 
the progression of eventual non-resected micrometas-
tases (80). However, such progression likely does not 
occur naturally in most cases (81).
Although some studies have reported low morbidity 
associated with central compartment lymph node elec-
tive dissection (79,82), other authors found a higher 
risk of transient and permanent hypoparathyroidism 
(83), even when the procedure is performed by experi-
enced surgeons.
The lymph nodes in the lateral compartments (II to 
IV) and the posterior triangle may also be affected by 
papillary thyroid cancer metastases (76). However, re-
moval of those lymph nodes appears to exert significant 
impact only on patients with clinically or US-detected 
metastases (68).
Recommendation 30
When affection of the central compartment lymph nodes 
is suspected, therapeutic dissection of this compartment 
is indicated (Recommendation A). When the presence 
of metastasis is confirmed in the pre- or perioperative 
period, dissection must include the lymph nodes in the 
ipsilateral compartment (Recommendation B).
Recommendation 31
When affection of the lymph nodes in the lateral com-
partments is suspected, therapeutic dissection of these 
compartments is indicated (Recommendation A). When 
the presence of metastases is confirmed in the pre- or 
perioperative period, dissection must include the central 
compartment lymph nodes (Recommendation B).
Recommendation 32
In patients without suspected metastases on preope-
rative US and the surgeon’s perioperative assessment, 
elective dissection of the central compartment lymph 
nodes may be considered when the tumors are > 4 cm 
or there is apparent extrathyroidal invasion (Recom-
mendation C).
Although the BRAF gene mutation is associated 
with greater initial aggressiveness of papillary carcino-
ma, including higher frequency of lymph node metas-
tases, the available data are not sufficient to rule out or 
indicate elective dissection of the central compartment 
lymph nodes on the grounds of the absence or presence 
of this mutation, respectively (84,85).
How must staging be performed after surgery?
The aims of postoperative staging are as follows: 1) to 
estimate the mortality risk; 2) to establish the risk of 
relapse; 3) to assess the quality of surgery; 4) to define 
the initial individualized treatment; and 5) to make the 
terms uniform and facilitate the communication among 
the multidisciplinary staff that participates in patient 
treatment and follow up. 
The staging system formulated by the American Joint 
Committee on Cancer/International Union against 
Cancer (AJCC/UICC) based on the tumor size, extra-
thyroidal invasion, lymph node and distant metastases 
(TNM), and age is recommended for all tumor types 
including thyroid tumors as an attempt to standardize 
the description of tumor extent. As that system does not 
consider other factors known to influence the progres-
sion and prognosis of DTC patients, its ability to predict 
the persistence and relapse of these tumors is limited, 
whereas it is more useful in the estimation of the mor-
tality rate associated with the disease. In any case, the 
tumor size, presence and extent of extrathyroidal inva-
sion and lymph node and distant metastases are relevant 
parameters in the choice of the initial treatment. 
Some histological variants such as tall and colum-
nar cells, extensively invasive follicular carcinoma, and 
poorly differentiated carcinoma exhibit more aggres-
sive behavior (72,78). Other signs of a poor progno-
sis include considerable nuclear atypia, tumor necrosis, 
and vascular invasion, all of which suggest lower grades 
of tumor differentiation (86).
The impact of lymph node compromise on the prog-
nosis is controversial. According to prevailing opinions, 
lymph node metastases that are macroscopic, present in 
large numbers or characterized by extracapsular exten-
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sion increase the risk of relapse and mortality in patients 
older than 45 years old (87,88).
Therefore, we describe four categories of risk of per-
sistent or recurrent disease in table 5. 
We excluded children and adolescents from that 
stratification, as the classification of risk should be par-
ticularized in those cases because, despite the high fre-
quency of cases of disease not restricted to the thyroid, 
their long-term prognosis is excellent (67,72).
Recommendation 33
The initial staging of patients must be performed accor-
ding to the TNM system. However, the stratification of 
risk must also consider other anatomical-pathological 
data (histological subtype, vascular invasion, free or 
affected margins) as well as the postoperative assess-
ment to achieve better estimates of the risk of recurren-
ce (Recommendation B).
How are the tissues remaining after surgery quantified?
Even when thyroidectomy is reported to be total, 
quantification of the remaining thyroid tissue is re-
commended, especially when surgery is performed by 
a surgeon with little or unknown experience. For that 
purpose, neck US is superior to scintigraphy and also 
provides information on the persistence of lymph node 
metastases (89,90). For this purpose, a 3-month inter-
val is required between surgery and ultrasonographic 
assessment (90). The analysis of vascularization using 
Doppler can be helpful in the differential diagnosis of 
Table 5. Stratification of the risk of recurrence
Anatomopathological data and postoperative information
Risk
Tumor size and 
extrathyroidal 
invasion
Lymph node 
metastasis Distant metastasis Histology Tumor resection
b Uptake on WBS
High (any finding)
Extensive 
extrathyroidal 
invasion (pT4)
> 10 affected LN or 
> 3 LN with ECE or 
any metastatic lymph 
node > 3 cm
M1a Incomplete Distant (M1)
Intermediate (any 
finding)
> 4 cm
4-10 affectedLN or 
1-3 LN with ECE
Aggressive subtype 
or vascular invasion
Neck ectopic (LN)
Intermediate (both 
findings)
≤ 4 cm with minimal 
extrathyroidal 
invasion (pT3)
1-3 LN without ECE
2-4 cm without 
extrathyroidal 
invasion (pT2)
1-3 LN without ECE
2-4 cm with minimal 
extrathyroidal 
invasion (pT3)
cN0c
Low (all findings)
≤ 4 cm without 
extrathyroidal 
invasion
cN0c
M0a
Classic, without 
vascular invasion
Complete Thyroid bedd
≤ 2 cm without 
extrathyroidal 
invasion (pT1)
1-3 LN without ECE
≤ 2 cm with minimal 
extrathyroidal 
invasion (pT3)
cN0c
Very low (all findings)
≤ 1 cm without 
extrathyroidal 
invasion (pT1a)
cN0c M0a
Classic, without 
vascular invasion
Complete1-2 cm without 
extrathyroidal 
invasion (pT1b), 
single
LN: lymph nodes; ECE: LN: extracapsular extent; WBS: whole body scan.
a Detected on clinical or radiological assessment or post therapy WBS; b Based on the surgeon’s description and postoperative assessment; c cN0: without metastases on pre- US and perioperative 
assessment, with (pN0) or without (pNx) elective dissection; d Only when 131I ablation is indicated.
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lesions in the thyroid bed and in determining whether 
the lymph nodes are benign or metastatic.
Recommendation 34
Measurement of thyroid remnants and postoperative 
assessment of the neck must be preferentially perfor-
med using a Doppler US (Recommendation B).
Recommendation 35
Surgical reinterventions should be considered when the 
US shows large thyroid remnants or lymph node me-
tastases (Recommendation B).
When is 131I ablation/therapy indicated after total 
thyroidectomy? 
Treatment with 131I is indicated for patients with in-
complete tumor resection or apparent metastases after 
thyroidectomy and who are not candidates for surgical 
reintervention. In patients with apparently complete 
tumor resection but high or intermediate risk of per-
sistent disease (87,91), adjuvant 131I therapy impacts 
prognosis (92) and is thus recommended.
131I ablation is not indicated for very low-risk pa-
tients (67,72,73,75,93-95).
In the remainder of patients, i.e., those with a low risk 
of persistent/recurrent disease, ablation is controversial 
(67,96). In such cases, administration of 131I may confer 
additional benefits such as improvement of the serum 
Tg specificity and the early detection of metastasis on a 
whole body scan (WBS). Nevertheless, in patients with 
stimulated Tg levels ≤ 1 ng/ml and no abnormalities on 
an US a few months after thyroidectomy, the specificity 
of that marker is not affected by the remaining tissue; it 
is known that a WBS after 131I administration does not 
detect metastases (97,98); and the risk of relapse is low, 
even when 131I is not administered (90,99,100). For 
those reasons, this criterion suggests to dismiss ablation 
in the low-risk group (90,97-100).
Indication for 131I must also consider the cost of 
treatment as well as its potential adverse effects such 
as transient alterations of the gonadal function (101-
103), acute sialadenitis (103), early menopause (104), 
and persistent xerostomia and xerophthalmia (105) in 
addition to a higher risk of second cancers (106).
Recommendation 36
131I is indicated for patients subjected to total thyroi-
dectomy and with known tumor persistence or high or 
intermediate risk of relapse (Recommendation B). With 
regard to low-risk patients, ablation should be dismissed 
when stimulated Tg levels are ≤ 1 ng/ml after surgery 
(Recommendation B). Ablation is not indicated in cases 
with a very low risk of relapse (Recommendation B).
How should TSH stimulation be performed before 131I 
ablation/therapy?
Human recombinant TSH is the pre-treatment proce-
dure indicated for patients with conditions potentially 
aggravated by hypothyroidism [such as heart, lung, or 
atherosclerotic disease, kidney failure, severe depres-
sion, old age, and weakening diseases (107)] or with 
an inability to raise endogenous TSH to satisfactory 
levels (as in hypopituitarism). Even when none such 
condition is present, recombinant TSH is preferable 
when it is available in patients with complete tumor 
resection and no apparent metastasis after thyroidec-
tomy because it is known to be efficacious in such 
cases (108-112). Furthermore, recombinant TSH 
exhibits advantages over discontinuation of T4: the 
quality of life of the patients is not affected; it elimina-
tes the symptoms and eventual risk of hypothyroidism; 
and it is associated with shorter leaves of absence, less 
extrathyroidal radiation, and shorter exposure to high 
TSH levels (103,108,109,111,113). In the remainder 
of patients (incomplete tumor resection or persistent 
metastases), discontinuation of T4 over 3 or 4 weeks is 
still the most proper indication in the absence of clinical 
contraindications. The latter recommendation also ap-
plies to children and adolescents because although the 
use of recombinant TSH is safe and apparently effica-
cious in them (114), further studies are required.
To perform 131I ablation or therapy, one ampoule of 
recombinant TSH (0.9 mg) is administered intramus-
cularly on two consecutive days followed by 131I admin-
istration 24 hours after the second dose. 
Recommendation 37
In the presence of clinical conditions potentially ag-
gravated by hypothyroidism, recombinant TSH is the 
recommended pre-treatment (Recommendation A). 
In the absence of such conditions, the discontinuation 
of T4 is recommended in patients with known tumor 
persistence, as well as in both children and adolescents 
(Recommendation C). In the remainder of patients, re-
combinant TSH is recommended whenever it is availa-
ble (Recommendation A).
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What 131I activity should be administered?
In patients with low risk of persistent or recurrent di-
sease and in whom a total thyroidectomy was properly 
performed, an activity of 30 mCi of 131I is efficacious 
to achieve remnant ablation (108,109,115-118) and 
exhibits low medium- and long-term relapse rates 
(67,93,117,119). In this regard, two major randomi-
zed trials with 438 (108) and 756 (109) patients stand 
out. Both studies showed clearly that the efficacy of 30 
mCi for the purpose of ablation was the same compa-
red to 100 mCi independent of the pre-treatment, i.e., 
discontinuation of T4 or recombinant TSH (108,109). 
When the size of the thyroid remnant is uncertain, the 
parameters to indicate an activity of 30 mCi are the 
volume measured on US (≤ 2 g), thyroid bed uptake 
[≤ 2% (108,109,115)], or postoperative Tg levels (97). 
Activities of 200 mCi or greater require caution 
when dosimetry is not available, particularly in the case 
of elderly or patients with diffuse lung metastases, be-
cause the maximum tolerated activity is commonly ex-
ceeded in such cases (120).
Recommendation 38
In low-risk patients, an activity of 30 mCi is preferable, 
whereas a 100-mCi activity is reserved for cases with 
known large tissue remnants (Recommendation A).
Recommendation 39
In patients without apparent disease, but intermediate 
or high risk, activity of 100 mCi is recommended (Re-
commendation B).
Recommendation 40
In patients with local-regional tumor persistence, who 
are not candidates for surgical reintervention, activities 
of 100 or 150 mCi are recommended (Recommenda-
tion B).
Recommendation 41
An activity of 200 mCi should only be considered for 
adults with known distant metastases (Recommenda-
tion B).
What other recommendations are important in 131I 
ablation/therapy?
A low-iodine diet, usually ≤ 50 µg/day for 7 to 14 days 
before the administration of 131I, appears to increase the 
uptake and radiation dose in the lesions (121). Never-
theless, the influence of a low-iodine diet on the success 
rate of ablation/therapy has not yet been demonstrated 
in a convincing manner (121). The corresponding stu-
dies are few, and none included a long-term assessment 
of the relapse and mortality rates (121). In addition to 
diet, other sources of iodine should be investigated (e.g., 
medications, syrups, dietary supplements, topic solu-
tions, cosmetics). In addition, iodinated contrast agents 
are an important source of contamination, whose com-
plete elimination requires at least one month (71).
Administration of furosemide and/or lithium be-
fore 131I may increase its uptake and the success rate 
of ablation performed with low 131I activity (116,118); 
however, the available evidence does not suffice to re-
commend it as routine. 
Recommendation 42
Despite its controversial benefit, a low-iodine diet must 
be prescribed due to its potentially positive effect and 
low cost (Recommendation B).
Recommendation 43
Women of reproductive age should be subjected to 
clinical and laboratory assessment (measurement of 
human chorionic gonadotropin; b-hCG) to rule out 
a pregnancy before administration of 131I. Pregnancy 
and breastfeeding are absolute contraindications to the 
use of RAI (Recommendation A). Women are advised 
to avoid conception for 6 to 12 months after RAI, and 
men are similarly advised for 3 months (Recommenda-
tion B).
What tests must be performed before and 
immediately after 131I ablation/therapy?
When TSH levels are > 30 mIU/l, Tg levels after total 
thyroidectomy and immediately before ablation bear a 
direct correlation with the presence of persistent metas-
tasis and WBS after treatment with RAI (67,97,122), 
are predictive of the success of the ablation (97,123), 
and behave as an important long-term prognostic fac-
tor (122,124,125). In addition, in the patients with 
elevated Tg levels after initial treatment, comparison 
with the Tg levels obtained during the ablation is pre-
dictive of the clinical outcome (124,125).
WBS before RAI treatment exhibits a lower sensiti-
vity for metastases compared to WBS after RAI treat-
ment (126) and may also be associated with a risk of 
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stunning, delayed treatment, and higher costs. Con-
versely, the post-treatment WBS exhibits higher sensi-
tivity and is able to identify unsuspected metastases (67
,87,91,97,98,109,111,122,126). Physiological uptake, 
or false-positive WBS results after treatment with RAI 
must be suspected when Tg is undetectable or low at 
the time of ablation [in the absence of anti-Tg anti-
bodies (TgAb)], when there is a lack of radiological 
correspondence to uptake, or when uptake occurs in 
sites unusual for metastases, particularly when isolated 
(127).
Recommendation 44
Measurement of serum Tg and TgAb must be per-
formed immediately before 131I administration (Re-
commendation B).
Recommendation 45
In patients with known anatomical-pathological and 
surgical data, WBS prior to treatment with RAI is not 
recommended (Recommendation B).
Recommendation 46
WBS must be performed 5 to 7 days after 131I admi-
nistration in any patient subjected to this therapy (Re-
commendation B). When the results of WBS after 
treatment with RAI are suggestive of metastasis, it is 
recommended to complement the assessment with an 
additional method to image the area corresponding to 
ectopic uptake (Recommendation B).
What is the approach in patients already 
subjected to thyroidectomy but with insufficient 
anatomopathological data for risk stratification?
In this circumstance, the assessment of the thyroid re-
mnants and the determination of the presence of me-
tastases are important. Initial assessment comprises cli-
nical examination, serum Tg [T4] (i.e., without TSH 
stimulation) and TgAb levels, neck US, and simple 
chest x-rays. Surgical reintervention must be conside-
red when large thyroid remnants (128) or lymph node 
metastases are found. When neither US nor x-rays show 
abnormalities, but Tg [T4] levels are higher than 1 ng/
ml, it is recommended to administer 30 or 100 mCi of 
131I based on Tg [T4] levels. When the initial assess-
ment rules out persistent disease, stimulated Tg must 
be performed (following discontinuation of T4 or use 
of recombinant TSH) together with a diagnostic WBS. 
An activity of 100 mCi of 131I is recommended when 
stimulated Tg levels are greater than 10 ng/ml under 
hypothyroidism or 5 ng/ml after use of recombinant 
TSH and a negative WBS. An activity of 100 to 200 
mCi is recommended when WBS shows ectopic uptake, 
depending on the extent of the metastases. 
Recommendation 47
In patients undergoing thyroidectomy, but whose ana-
tomopathological data are not sufficient to establish 
appropriate risk stratification, a more thorough pos-
toperative assessment is needed to determine the need 
for surgical reintervention and 131I ablation or therapy 
(Recommendation A).
When must external radiotherapy be included in the 
initial treatment?
Recommendation 48
External radiotherapy must be considered for patients 
with incomplete tumor resection, who are not candi-
dates for surgical reintervention, and when the tumor 
remnants exhibit low 131I uptake (Recommendation B).
When must T4 replacement be initiated?
In very low-risk individuals without indication for 131I 
administration, T4 replacement must be initiated imme-
diately after surgery. When recombinant TSH is used, 
there is no justification to delay T4 replacement. Similar-
ly, in the case of low-risk patients in whom the decision 
to perform 131I ablation depends on the Tg level appro-
ximately 12 weeks after surgery, hormone replacement 
must be initiated early. Finally, when the clinical, histo-
logical, and radiological data indicate the need for 131I 
ablation/therapy, and the 131I ablation/therapy will be 
performed within four weeks, T4 replacement may be 
delayed following thyroidectomy. However, when 131I 
ablation/therapy is scheduled for a later period, T4 re-
placement must be initiated after surgery to avoid long-
-lasting hypothyroidism, and then discontinued.
When 131I ablation/therapy is preceded by discon-
tinuation of T4, hormone replacement must be restarted 
early, i.e., 48 hours after the administration of RAI, and 
at the full dose to promote rapid TSH reduction (113).
Recommendation 49
T4 therapy must be initiated as early as possible (Re-
commendation B).
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What is the indicated TSH level following initial 
treatment?
In patients with well-differentiated tumors, TSH su-
ppression is an important adjuvant therapy. In indivi-
duals with known metastasis, TSH suppression has an 
inhibitory action on tumor growth and disease pro-
gression (67). In patients without apparent disease but 
with elevated Tg levels, low TSH levels contribute to 
the long-term negation of this marker (129). In addi-
tion, in cases without apparent disease but high risk of 
relapse, TSH suppression is associated with improved 
outcomes (130,131). Even in low-risk patients under 
full remission, TSH levels persistently over 2 mIU/ml 
are associated with worse long-term progression (132).
Subclinical thyrotoxicosis is associated with bone 
mass compromise, especially among postmenopausal 
women (57,58,133), and morphological and functional 
heart disorders (57,58), which have more clinical reper-
cussions among older adults. To minimize the adverse 
effects of suppressive therapy with T4, some steps are 
important. First, clinicians should pay attention to the 
fact that the TSH target must be individualized and sub-
jected to constant reassessment (134), taking the pres-
ence of metastasis, Tg levels, and risk of relapse into ac-
count (Figure 2). Second, truly undetectable TSH is not 
necessary, and high serum T4 and especially T3 levels, 
must be avoided. Third, in addition to appropriate cal-
cium and vitamin D intake (in all), periodic cardiovascu-
lar assessment (all) and bone densitometry (postmeno-
pausal women) are recommended in patients subjected 
to TSH suppression for long periods of time. Finally, if 
the TSH suppression persists, in addition to their usual 
therapeutic indications, beta-blockers must be consi-
dered in patients with heart symptoms or morphological 
alterations, as well as the use of bisphosphonates in post-
menopausal women with osteopenia (57,58).
To avoid long periods outside the target, it is re-
commended to measure TSH levels 6 to 8 weeks after 
the onset of replacement therapy or after any change in 
the dose or commercial formulation of T4 and every six 
months once the desired levels are achieved, provided 
the dose is kept unchanged. 
Recommendation 50
The level of TSH suppression must be individuali-
zed according to the ongoing disease state (Recom-
mendation B). Measures to monitor and prevent the 
negative effects of TSH suppression must be applied to 
patients subjected to TSH suppression for long periods 
of time (Recommendation B).
What are the recommendations relative to the 
method for thyroglobulin measurement?
Measurement of Tg is not a trivial laboratory exam (135). 
Although a number of limitations are minimized by highly 
sensitive immunometric methods, others remain (135):
1. Lack of international standards, resulting in va-
riability of the available methods.
2. Excessively high inter-assay variability, espe-
cially when we consider the usual interval bet-
ween sample collections during the follow up 
of patients with differentiated carcinoma (6 to 
12 months). Therefore, to reduce the inter-as-
say error, the laboratories should keep samples 
frozen for at least one year to process the older 
sample together with the newer one.
3. Possibility of a “hook effect”, especially in the 
immunometric assays, leading to inappropria-
tely low results in patients with very high Tg 
levels. To avoid this effect, the tests should be 
systematically performed in two steps.
4. The presence of TgAb in the serum can elicit fal-
se low Tg results in immunometric assays (136). 
Therefore, investigation of TgAb is mandatory, Figure 2. Recommended TSH levels after initial treatment in patients with differentiated thyroid cancer.
 Thyroidectomy
 
Without 131|  ablation  131|
TSH 0.5-2 mIU/L RxWBS  
Metastases
TSH ≤ 0.1 mIU/L Low risk: TSH 0.1-0.5 mIU/L
High risk: TSH ≤ 0.1 mIU/L
Elevated Tg or TgAb
(without apparent
disease)
Negative
Low risk: TSH 0.1-0.5 mIU/L
High risk: TSH ≤ 0.1 mIU/L
Low risk: TSH 0.5-2 mIU/L
High risk: TSH 0.1-0.5 mIU/L 
in the rst 5 years
Control assessment
Complete remissionMetastases
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and whenever positive, the laboratory must call 
attention to the possibility of false-negative Tg 
results. In such cases, quantitative investigation 
of serum Tg mRNA may be an alternative (137); 
however, it is not yet available in clinical practice.
What is the recommendation for the initial 
assessment of patients who were not given 131I?
Recommendation 51
For very low-risk patients not subjected to treatment 
with 131I, it is recommended to measure Tg [T4] and 
TgAb levels and to perform a neck US six months after 
thyroidectomy. The patients with serum Tg [T4] levels 
≤ 1 ng/ml, no TgAb, and no abnormal findings on 
US are considered to be disease free; therefore, the 
measurement of stimulated Tg is not needed (Recom-
mendation B). When Tg [T4] levels are higher than 1 
ng/ml, or the TgAb assay is positive, patient manage-
ment will depend on the behavior of these markers, i.e., a 
more thorough investigation (in case of increase) or only 
monitoring (in case of decrease) (Recommendation B).
What exams must be performed at the initial 
assessment following ablation?
In the patients in whom WBS after RAI treatment does 
not show ectopic uptake, six months after ablation, me-
asurement of Tg [T4] and TgAb levels and neck US are 
recommended. 
At that moment, most patients exhibit Tg [T4] levels 
≤ 1 ng/ml, a negative TgAb, and no abnormal findings 
on US. In that case, stimulated Tg ought to be mea-
sured 9 to 12 months after ablation (138-140). Ultra-
sensitive Tg tests (functional sensitivity ≤ 0.2 ng/ml) are 
available in Brazil and may reduce the need to measure 
stimulated Tg (141). Indeed, when Tg is measured us-
ing these tests, stimulation becomes unnecessary in 
low-risk patients with undetectable Tg [T4] levels, no 
TgAc interference, and negative US findings (141-145). 
Diagnostic WBS concomitant with stimulated Tg may 
be helpful in intermediate- or high-risk patients (140); 
however, its value has not been established (138).
In the patients with undetectable Tg [T4] levels 
and negative US findings but circulating TgAb, stimu-
lated Tg associated with diagnostic WBS may be useful 
(146). However, if TgAb was assessed earlier, usually 
at the time of ablation, and the ongoing levels show 
a reduction of > 50% of their titer (147), neither 
stimulated Tg nor diagnostic WBS are necessary. 
To avoid stunning, diagnostic WBS must be per-
formed with 123I, 2 mCi of 131I (148), or tracer activity 
of 5 mCi of 131I, provided that the 131I therapy (when-
ever necessary) is performed 3 to 5 days later (149).
TSH levels > 30 mIU/ml are necessary to accom-
plish appropriate Tg stimulation and WBS and are 
achieved by a total (3 to 4 weeks) or partial (6 to 8 
weeks) discontinuation of T4 (150) or administration 
of recombinant TSH. When hypothyroidism is contra-
indicated or endogenous TSH is unable to increase to 
appropriate levels, use of recombinant TSH is the only 
available option. In the remainder of cases, due to the 
above-mentioned advantages, use of recombinant TSH 
is systematically preferred, when available.
For the purpose of Tg stimulation, one ampoule 
(0.9 mg) of TSH is administered intramuscularly on 
two consecutive days; the Tg levels should be measured 
72 hours after the second dose. 
Recommendation 52
Measurement of serum Tg [T4] and TgAb levels and a 
neck US must be performed six months following abla-
tion. Stimulated Tg (9 to 12 months after ablation) is 
recommended when the earlier results were negative, 
except for low-risk patients with undetectable Tg [T4] 
levels on an ultrasensitive test and no TgAb interferen-
ce (Recommendation B). Diagnostic WBS (associated 
with stimulated Tg) may be useful in intermediate- or 
high-risk patients (Recommendation C).
Recommendation 53
In patients with undetectable Tg [T4] levels and a nega-
tive US but circulating TgAb, stimulated Tg associated 
with a diagnostic WBS may be useful (Recommenda-
tion C); however, those tests are not necessary when the 
TgAb titers decrease by > 50% (Recommendation B).
What is the recommended investigation in patients 
with high Tg and negative US?
In patients with Tg [T4] levels > 1 ng/ml and a ne-
gative neck US, the initial step is to perform a chest 
and mediastinal CT. When no abnormalities are thus 
found, one may decide to merely monitor the Tg 
behavior later or to perform a more thorough in-
vestigation based on the Tg [T4] levels and the pa-
tient risk category. In the latter case, the traditional 
recommendation is to perform WBS after the use of 
radioiodine (100 mCi 131I) followed by 18FDG-PET 
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(139,151); however, the latter might also be the first 
step (138,152,153).
When negative Tg [T4] levels increase to levels above 
1 ng/ml following TSH-induced stimulation and metas-
tases are not found at the initial assessment, conservative 
management is recommended when Tg is less than 10 
ng/ml following discontinuation of T4 or 5 ng/ml with 
use of recombinant TSH (91,124,125,138). When the 
Tg levels are higher, a more thorough investigation is rec-
ommended, as mentioned above. Many patients with ele-
vated Tg and no apparent disease progress late into com-
plete remission (91,112,124,125,138,151,152,154).
Recommendation 54
In patients with Tg [T4] levels greater than 1 ng/ml 
or stimulated Tg higher than 5 ng/ml (with recombi-
nant TSH) or 10 ng/ml (under hypothyroidism), chest 
and mediastinal CT followed by WBS after an empirical 
dose (of 100 mCi) of 131I and/or 18FDG-PET is recom-
mended (Recommendation B).
How should cervical lymphadenopathy be managed?
US is the most sensitive method to detect neck me-
tastases (122,140,142,144,155); however, its sensiti-
vity depends on the examiner’s experience and ability 
(156). Lymph nodes larger than 5 mm must be inves-
tigated only when they exhibit micro-calcifications or 
cystic degeneration or, in the absence of these findings, 
if they are round and lack an echogenic hilum or are 
hypervascular based on Doppler results (98,140,157-
160). FNA is crucial to establish the nature of suspi-
cious lymph nodes; therefore, the biopsied tissue must 
be subjected to cytological analysis and Tg should be 
measured in the needle washing fluid (158,160).
Recommendation 55
US is the best method to assess neck lymph nodes. 
Cytological analysis of the FNA material and measure-
ment of Tg in the aspirated fluid are recommended in 
suspicious lymph nodes (Recommendation B).
How should patients who achieve complete 
remission after treatment be monitored?
Recommendation 56
The patients who achieve complete remission (unde-
tectable Tg, no TgAb, and negative findings on the 
imaging methods) following treatment are at low risk 
of relapse in the long term (87,90,91,112,138,143). 
Therefore, these patients may be assessed once per year 
by means of a clinical examination and measurement 
of serum Tg [T4] and TgAb levels (Recommendation 
B). Neck US must be performed annually the first five 
years in intermediate- or high-risk patients, whereas it 
is optional or may be performed at longer intervals in 
low-risk patients (Recommendation B). The long-term 
recommended TSH levels are shown in Figure 2. In 
case TgAb or Tg [T4] levels become persistently de-
tectable, and more particularly, when they exhibit pro-
gressive increase, and US shows no abnormal findings, 
investigation must include other imaging methods such 
as chest and mediastinal CT, WBS after RAI treatment, 
or FDG-PET (Recommendation B). The need to re-
peat stimulated Tg in patients who maintain negative 
findings of Tg [T4], TgAb, and US is doubtful. If it is, 
indeed, performed, it should not be too soon after the 
first negative stimulated Tg test [i.e., < five years (161)].
Recommendation  57
In the cases where only the TgAb are elevated, an an-
nual measurement of Tg [T4] and TgAb levels and the 
performance of the US are recommended (Recom-
mendation B). Abnormalities on the US, the persistent 
and progressive increase of TgAb titers, and elevated 
Tg [T4] levels point to tumor recurrence, indicating 
the need for further investigation by means of other 
imaging methods (Recommendation B). Conversely, 
disappearance of TgAb with undetectable Tg [T4] and 
negative US findings are indicative of remission (Re-
commendation B).
How should the patients with elevated thyroglobulin 
without apparent disease at the initial assessment 
be monitored? 
Recommendation 58
When the initial assessment does not reveal disease, mo-
nitoring by means of serum Tg [T4] and TgAb l levels, 
a neck US, and maintenance of TSH suppression (Figu-
re 2) are recommended. In the cases where elevated sti-
mulated Tg is the only finding, a second test is recom-
mended 18-24 months later. Whenever Tg increases, 
the clinical investigation must be furthered (chest and 
mediastinal CT, WBS following the use of an empirical 
131I dose, FDG-PET). As long as Tg levels are stable 
or decreasing, no further investigation is needed, and 
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the clinical outcome will be most likely be satisfactory 
(91,112,124,138,151,154). Finally, the patients with 
undetectable stimulated Tg should be monitored as if 
they were in complete remission (Recommendation B).
Metastatic disease
When surgical treatment and 131I therapy associated 
with TSH suppression (≤ 0.1 mIU/L) (162) do not 
suffice to control metastatic disease, external radio-
therapy should be considered depending on the site. 
Conventional chemotherapy has proven to induce a 
limited benefit but considerable morbidity in patients 
with progressive disease, in spite of the measures des-
cribed above (163). New therapeutic approaches based 
on molecular targeted therapies are currently emerging 
as promising alternatives in such cases (164,165). Ho-
wever, the recommendation to use those new drugs in 
clinical practice must be cautious, as a large number 
of the new drugs are still under investigation and their 
availability is limited. In addition, their high cost and 
significant side effects (heart, gastrointestinal, and skin) 
must be considered. Whether synergistic drug combi-
nations exhibit better cost-benefit ratios and less mor-
bidity remains to be determined (166).
What is the approach for local-regional disease?
Five to 20% of patients with DTC exhibit local or re-
gional recurrence, which is approximately twice the fre-
quency of the distant metastases (67,72,167).
The most widely indicated treatment of local-re-
gional disease is surgical excision, especially in the ab-
sence of distant metastases. Most surgeons recommend 
extending the exploration beyond the apparently af-
fected compartments because the extent of the meta-
static disease tends to be larger than suggested by the 
imaging exams, but this exploration should preserve 
the vital structures (168). Approximately 30-50% of the 
patients attain complete remission shortly after surgical 
reintervention (169).
In recent years, US-guided percutaneous ethanol 
injection of metastatic lymph nodes has emerged as a 
therapeutic possibility for patients with papillary carci-
noma and a limited number of metastases (170,171).
In tumors that invade the upper airway and/or 
digestive tract, aggressive surgery seeking to resect as 
much affected tissue as possible, while preserving or-
gan function is recommended. Surgery may include 
tracheal resection with anastomosis or esophagophar-
yngectomy (172).
Recommendation 59
Therapeutic dissection is indicated in metastases loca-
ted in the central compartment; and careful pre- and 
perioperative assessment is required to define the ex-
tent of the procedure in the lateral compartments (Re-
commendation B). Therapeutic dissection is indicated 
in metastases located in the lateral compartments (Re-
commendation B), and dissection of the central com-
partment lymph nodes is also indicated when it was not 
performed initially (Recommendation B).
Recommendation 60
When surgical resection is not complete or possible, 
and the tumor has 131I uptake, the patient should be 
subjected to treatment with 131I (Recommendation B).
In patients treated with 131I, lack of ectopic uptake 
on WBS after treatment, associated with negative stim-
ulated Tg is predictive of low risk of relapse (173).
Recommendation 61
Whenever it is technically possible, extensive surgery is 
indicated for tumors that invade the upper airway and/
or digestive tract, provided that the surgery can be 
performed by surgeons with broad experience in these 
procedures and reinterventions and can subsequently 
be combined with radioactive iodine therapy when the 
tumor demonstrates 131I uptake (Recommendation B).
Recommendation 62
External radiotherapy is indicated in patients with clini-
cally significant, non-resectable, local-regional disease 
without 131I uptake (Recommendation B).
Distant metastases: general considerations
The patients with DTC and distant metastases exhibit 
increased mortality and morbidity (67,72). Neverthe-
less, the negative impact of metastases depends on their 
number, localization, and size as well as on the pa-
tient age and tumor 131I uptake (174,175). Whenever 
metastases are resectable, surgery is the treatment of 
choice, provided its associated morbidity is acceptable. 
In this regard, it is advisable for the procedure to be 
performed by a surgeon with wide experience in major 
surgery and reinterventions. The procedure must be 
aggressive, while seeking to preserve organ function. 
In this regard, the indication for highly aggressive sur-
gical procedures that compromise the overall state of 
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the patients without likelihood of curing them, or in 
the presence of multiple additional metastases, must be 
questioned. 
What is the approach in patients with lung 
metastases?
The treatment of lung macrometastases with 131I 
uptake is similar to the treatment of micrometastases. 
However, as the 131I uptake is not adequate in such tu-
mors, therapeutic alternatives must be taken into con-
sideration, such as surgical resection of the metastases, 
which must be performed whenever possible; palliative 
external radiotherapy in symptomatic intrathoracic tu-
mors; drainage of symptomatic pleural or pericardial ef-
fusions; tumor redifferentiation attempts (178); or use 
of the novel molecular-targeted drugs, which appear to 
induce better responses specifically in lung metastases 
(179,180).
Traditional chemotherapy has not proven to be use-
ful in patients with non-resectable tumors that do not 
exhibit 131I uptake (163).
Recommendation 63
Patients with lung micro- or macrometastases that de-
monstrate 131I uptake must be given 100 to 200 mCi of 
131I every 6 months during the first two years and then 
once per year. Most remissions occur at an accumula-
ted activity ≤ 600 mCi. Above this level, the eventual 
benefit of additional radioactive iodine therapy must be 
balanced with its potential risks (Recommendation B).
Recommendation 64
A large number of patients with lung macrometastases 
kept under suppressed TSH levels (≤ 0.1 mIU/L) have 
a good outcome and can be monitored in a conserva-
tive manner (Recommendation B). Other cases of lung 
macrometastases exhibit a more aggressive progression, 
and thus the palliative treatment of symptomatic lesions 
must be considered, including surgical resection, exter-
nal radiotherapy, and endobronchial laser ablation (Re-
commendation B).
Recommendation 65
Patients with progressive or symptomatic lung metastatic 
disease that is not responsive to conventional treatment 
should be encouraged to enroll in clinical trials for new 
drugs when available. For patients not included in clini-
cal trials, the off-label use of drugs commercially availa-
ble for other malignant tumors and previously investiga-
ted in DTC may be considered (Recommendation C).
What is the approach in patients with bone 
metastases?
Up to 40% of the patients with DTC and distant me-
tastases exhibit bone involvement, which is associated 
with a poorer prognosis (176). The survival of the pa-
tients with bone metastases is usually reduced due to 
the therapeutic challenge posed by the localization and 
extent of the lesions, which usually do not exhibit 131I 
uptake. In addition to the lower survival rates, the de-
velopment of bone metastases may result in significant 
morbidity due to pathologic fractures, intense pain, im-
mobility, and reduced quality of life (181). In clinical 
studies, the term skeletal-related events (SRE) is used 
to quantify the morbidity associated with bone metas-
tases (181). The clinical determinants that compose the 
SRE include spinal cord compression, pathologic frac-
tures, and the need for external radiotherapy or surgery 
to afford pain relief or control tumor-related hypercal-
cemia (181). The patients frequently exhibit patholo-
gic fractures that can involve the vertebrae, resulting in 
severe neurological problems, including disabling pain 
and paraplegia (182).
In addition to the clinical data, imaging resources 
are crucial to identify the presence, location, and ex-
tent of the bone lesions; skeletal CT or MRI and FDG-
PET/CT are the best currently available methods for 
this purpose (176).
When the number of bone metastases is limited, 
surgical resection significantly improves patient prog-
nosis and survival and may eventually also be curative 
(176,183,184). Bone lesions that exhibit 131I uptake 
are also associated with improved survival (176,184). 
The recommended 131I activity varies from 150 to 
200 mCi per cycle. In tumors located in critical ar-
eas close to neural structures, 131I-induced edema can 
cause nerve compression associated with severe pain 
and functional disability (182). In such cases, exter-
nal radiotherapy combined with corticosteroids must 
be considered (176,182). Radiotherapy is also indica-
ted for non-resectable metastases that do not exhibit 
131I uptake. Other procedures such as intra-arterial 
embolization, periodic pamidronate or zoledronate 
infusions, or cement injections may also be useful 
(185,186).
Selumetinib – a MEK1 and MEK2 inhibitor – 
represents a recent perspective in the treatment of 
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bone metastases, which appear to be more resistant 
to tyrosine kinase inhibitors; this drug significantly 
increases 131I uptake and reverts the refractoriness to 
131I (165).
Recommendation 66
Bone metastases must be subjected to surgical treat-
ment whenever possible. The treatment of non-resec-
table bone lesions that have 131I uptake consists of the 
administration of 150 or 200 mCi 131I per cycle. These 
therapeutic approaches improve patient quality of life 
and survival (Recommendation B).
Recommendation 67
In areas where the expansion of bone metastases indu-
ced by 131I or high TSH levels may cause neurological 
complications or pain, corticosteroid use is recommen-
ded (Recommendation B).
Recommendation 68
External radiotherapy is recommended for non-resec-
table metastases that are painful or symptomatic and 
are located in sites where the 131I-induced expansion 
is problematic or where they do not demonstrate 131I 
uptake (Recommendation B).
Recommendation 69
Patients with progressive or symptomatic bone metas-
tatic disease non-responsive to conventional treatment 
must be encouraged to enroll in clinical trials of new 
drugs when they are available (Recommendation C).
What is the approach for brain metastases?
Brain metastases are rare complications of DTC and oc-
cur more frequently among older adults with advanced 
stages of the disease. Nevertheless, these lesions may be 
the first manifestation or the first metastasis of thyroid 
cancer (187). Imaging exams such as CT and gadoli-
nium-based MRI (preferably) are usually able to reveal 
the tumor location and extent. A biopsy is frequently 
necessary to confirm that a lesion is a thyroid cancer me-
tastasis (188). Initial treatment is surgical and must at-
tempt a full resection of the metastases, as a full resection 
is associated with improved survival (187,188). These 
lesions do not usually exhibit 131I uptake, and treatment 
must thus include external radiotherapy or target-direc-
ted therapy (189).
Recommendation 70
The treatment of choice for brain metastases is the 
full surgical resection of the lesions (Recommenda-
tion B). As the lesions often do not exhibit 131I up-
take, external radiotherapy is indicated when surgery 
is not possible (Recommendation B), or the use of 
novel drugs must be considered, as indicated in R65 
(Recommendation C).
When should recombinant TSH be used in metastatic 
disease?
The possible use of recombinant TSH in the treatment 
of metastases that have 131I uptake has been assessed, 
and the response was seemingly similar to T4 withdra-
wal (182,190,191). A retrospective study showed 
that the five-year survival rate was similar in patients 
with lung or bone metastases prepared with either T4 
withdrawal or recombinant TSH before 131I therapy 
(190).
Recommendation 71
In the treatment of metastases with 131I, preparation 
with recombinant TSH is indicated in patients presen-
ting with clinical conditions that contraindicate discon-
tinuation of T4 (and the consequent hypothyroidism), 
who are unable to increase the endogenous TSH to 
satisfactory levels, are very debilitated, or old (Recom-
mendation B). Pre-treatment with corticosteroids is re-
commended in metastatic sites where the risk of expan-
sion due to edema and bleeding might be problematic 
(Recommendation B).
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